AMG 994 + AMG 404

AMG 994 + AMG 404 is an investigational **combination therapy** comprising two experimental monoclonal antibodies, AMG 994 (inezetamab) and AMG 404 (zeluvalimab), developed for the treatment of **advanced solid tumors**. AMG 994 is a bispecific antibody targeting both **CD40** (agonist) and **mesothelin** (inhibitor/antagonist), designed to enhance antitumor immunity by stimulating antigen-presenting cells and targeting tumor cells expressing mesothelin. AMG 404 is a monoclonal antibody that blocks **programmed cell death protein 1 (PD-1)**, acting as an immune checkpoint inhibitor to promote T-cell mediated antitumor responses. The combination aims to synergize direct tumor targeting and immune stimulation. Both drugs were developed by Amgen, with BeOne Medicines also associated with AMG 994[1][3][5].

Other names

inezetamab + zeluvalimab